Elicio Therapeutics received FDA feedback supporting ELI-002's Phase 3 study design; Phase 2 analysis results expected in H1 2025. Elicio Therapeutics announced positive feedback from the FDA ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results